Mitchell Chan

Director/Board Member at AVALO THERAPEUTICS, INC.

43 year

Health Technology

Consumer Services

Commercial Services

Profile

Mitchell Chan is an Independent Director at Avalo Therapeutics, Inc. and a Director at Maryland Technology Council.
He was previously a Director-Investor Relations at AstraZeneca PLC and the Chief Financial & Accounting Officer at Viela Bio, Inc. He holds an MBA from Rotman School of Management and undergraduate and graduate degrees from the University of Toronto.

Mitchell Chan active positions

Companies	Position	Start
AVALO THERAPEUTICS, INC.	Director/Board Member	2021-11-30
Maryland Technology Council Maryland Technology Council Miscellaneous Commercial ServicesCommercial Services The Maryland Technology Council functions as a technology trade association. The private company is based in Rockville, MD.	Director/Board Member	2020-03-10

All active positions of Mitchell Chan

Former positions of Mitchell Chan

Companies	Position	End
VIELA BIO, INC.	Director of Finance/CFO	2021-03-14
ASTRAZENECA PLC	Investor Relations Contact	-

See the detail of Mitchell Chan's experience

Training of Mitchell Chan

Rotman School of Management	Masters Business Admin
University of Toronto	Graduate Degree

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Mitchell Chan's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Listed companies	2
ASTRAZENECA PLC	Health Technology
AVALO THERAPEUTICS, INC.	Health Technology

Private companies	2
Maryland Technology Council Maryland Technology Council Miscellaneous Commercial ServicesCommercial Services The Maryland Technology Council functions as a technology trade association. The private company is based in Rockville, MD.	Commercial Services
Viela Bio, Inc. Viela Bio, Inc. BiotechnologyHealth Technology Viela Bio, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of treatment for autoimmune and inflammatory diseases. The firms product candidate includes inebilizumab, which is a humanized monoclonal antibody (mAb), designed to target CD19, a molecule expressed on the surface of a broad range of immune system B cells; VIB4920, which is a fusion protein designed to bind to CD40L on activated T cells, blocking their interaction with CD40-expressing B cells and potentially other binding partners; and VIB7734, which is a humanized mAb intended to be a novel treatment for autoimmune diseases where the pathology is driven principally by overproduction of type I interferons and other cytokines secreted by pDCs. The company was founded on December 11, 2017 and is headquartered in Gaithersburg, MD.	Health Technology